TOKYO (Reuters) - A potential acquisition of London-listed Shire by Takeda Pharmaceutical was greeted with investor scepticism about it merits on Thursday, with shares in the Japanese drug maker tumbling 7 percent.
UK: Merits of any Takeda bid for Shire questioned, shares slide
![UK: Merits of any Takeda bid for Shire questioned, shares slide]()
Reviewed by Shahid Karimi
on
March 29, 2018
Rating:
No comments: